• Molecular NameDezocine
  • SynonymDezocina [INN-Spanish]; Dezocinum [INN-Latin]
  • Weight245.366
  • Drugbank_IDDB01209
  • ACS_NO53648-55-8
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.29
  • pkaN/A
  • LogD (pH=7, predicted)0.51
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.36
  • LogSw (predicted, AB/LogsW2.0)0.06
  • Sw (mg/ml) (predicted, ACD/Labs)0.54
  • No.of HBond Donors3
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds0
  • TPSA46.25
  • StatusFDA approved
  • Administrationintramuscular injection
  • PharmacologyAn opioid analgesic related to pentazocine, with a similar profile of effects that include analgesic action and euphoria at low doses,[1] but produces dysphoria and hallucinations at high doses, most likely due to action at κ-opioid receptors.
  • Absorption_valueN/A
  • Absorption (description)Rapid and complete following intramuscular administration.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding92.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life2.2 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include cold and clammy skin, confusion, nervousness, or severe restlessness, convulsions (seizures), severe dizziness, severe drowsiness, low blood pressure, pinpoint pupils of eyes, slow heartbeat, slow or troubled breathing and severe weakness.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A